Effect of the in vivo priming regimen for peripheral blood stem cells (PBSC) mobilization on in vitro generation of cytotoxic effectors by IL-2 activation of PBSC in a murine model

Bone Marrow Transplantation

Volumn 19, Issue 3, 1997, Pages 265-273

  Verma, U N ^a   Yankelevich, B ^a   Hodgson, J ^a   Mazumder, A ^a,b  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

Cytotoxic cells; Hematopoietic precursors; Interleukin 2; Mobilizing regimens; PBSC

Indexed keywords

CD3 ANTIGEN; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 2; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; EFFECTOR CELL; FEMALE; HEMATOPOIESIS; INTRAPERITONEAL DRUG ADMINISTRATION; LYMPHOID CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL BLOOD STEM CELL; PHENOTYPE; PRIORITY JOURNAL; STEM CELL; STEM CELL TRANSPLANTATION; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031051375     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700632     Document Type: Article

References (28)

1. To LB, Roberts MM, Haylock DN et al. Comparison of hematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 1992; 9: 277-284.
2. Chao N, Schriber J, Grimes K et al. Granulocyte colony-stimulating factor 'mobilized' peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high dose chemotherapy. Blood 1993; 81: 2031-2035.
3. Barrett J, Horowitz MM, Gale RP et al. Marrow transplantation of acute lymphoblastic leukemia: factors affecting relapse and survival. Blood 1989; 74: 862-871.
4. Chopra R, Goldstone AH, Pearce R et al. Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case controlled analysis of the European bone marrow transplant group registry data. J Clin Oncol 1992; 10: 1690-1695.
5. Hardingham JE, Kotasek D, Sage RE et al. Molecular detection of residual lymphoma cells in peripheral blood stem cell harvests and following autologous transplantation. Bone Marrow Transplant 1993; 11: 15-20.
6. Liberti G, Pearce R, Taghipour G et al. Comparison of peripheral blood stem-cell and autologous bone marrow transplantation for lymphoma patients: a case-controlled analysis of the EBMT Registry data. Lymphoma Working Party of the EBMT. Ann Oncol 1994; 5 (Suppl. 2): 151-153.
7. Gribben JG, Freedman AS, Neuberg D et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B cell lymphoma. New Engl J Med 1991; 325: 1525-1533.
8. Brenner MK, Rill DR, Moen RC et al. Gene marking to trace origin of relapse after autologous bone marrow transplantation. Lancet 1993; 341: 85-86.
9. Truitt RL, Horowitz MM, Atasoylu AA et al. Graft-versus-leukemia effect of allogeneic bone marrow transplantation: clinical and experimental aspects of late leukemia relapse: In: Stewart THM, Wheelock FF (eds). Cellular Immune Mechanisms and Tumor Dormancy. CRC Press: Boca Raton, 1992, pp 111.
10. Charak BS, Brynes RK, Groshen S et al. Bone marrow transplantation with interleukin-2 activated bone marrow followed by interleukin-2 therapy for acute myeloid leukemia in mice. Blood 1990; 76: 2187-2190.
11. Klingemann HG, Eaves CJ, Barnet MJ et al. Transplantation of patients with high risk acute myeloid leukemia in first remission with autologous marrow cultured in interleukin-2 followed by interleukin-2 administration. Bone Marrow Transplant 1994; 14: 389-396.
12. Rajagopal C, Verma UN, Areman E et al. Induction of autologous visceral graft-versus-host disease (GVHD) with IL-2 activated peripheral blood stem cell (PBSC) transplantation. Blood 1994; 84: 333a (Abstr.).
13. Kessinger A, Armitage JO. The evolving role of autologous peripheral stem cell transplantation following high-dose therapy for malignancies. Blood 1991; 77: 211-213.
14. Liu K-Y, Akashi K, Harada M et al. Kinetics of circulating hematopoietic progenitors during chemotherapy-induced mobilization with or without granulocyte colony-stimulating factor. Br J Haematol 1993; 84: 31-38.
15. + cells. Blood 1994; 84: 2930-2939.
16. Rosenberg SA, Yang JC, Topalian SL et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA 1994; 271: 907-913.
17. Koretz MJ, Lawson DH, York RM et al. Randomized study of interleukin-2 (IL-2) alone vs IL-2 plus lymphokine activated killer cells for treatment of melanoma and renal cell cancer. Arch Surg 1991; 126: 898-903.
18. Lotze MT, Matory YL, Ettinghausen SE et al. In vivo administration of purified human interleukin-2: II. Half life, immunological effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL-2. J Immunol 1985; 135: 2865-2875.
19. Gottlieb DJ, Prentice HG, Heslop HE et al. Effects of recombinant interleukin-2 administration on cytotoxic effector function following intensive chemo-radiotherapy for hematological malignancy. Blood 1989; 74: 2335-2342.
20. Cuturi MC, Anegon I, Sherman F et al. Production of hematopoietic colony-stimulating factors by human natural killer cells. J Exp Med 1989; 169: 569-583.
21. Neben S, Marcus K, Mauch P. Mobilization of hematopoietic stem and progenitor cell subpopulations from the marrow to the blood of mice following cyclophosphamide and/or granulocyte colony-stimulating factor. Blood 1993; 81: 1960-1967.
22. Verma UN, Bagg A, Brown E, Mazumder A. Interleukin-2 activation of human bone marrow in long-term cultures: an effective strategy for purging and generation of anti-tumor cytotoxic effectors. Bone Marrow Transplant 1994; 13: 115-123.
23. Verma UN, Areman E, Dickerson SA et al. Interleukin-2 activation of chemotherapy and growth factor mobilized peripheral blood stem cells for generation of cytotoxic effectors. Bone Marrow Transplant 1995; 15: 199-206.
24. Shibuya A, Taguchi K, Kojima H, Abe T. Inhibitory effect of granulocyte-macrophage colony-stimulating factor therapy on generation of NK cells. Blood 1991; 78: 3241-3247.
25. Taguchi K, Shibuya A, Inazawa Y, Abe T. Suppressive effect of granulocyte-macrophage colony-stimulating factor on the generation of natural killer cells in vitro. Blood 1992; 79: 3227-3232.
26. Rajagopal C, Verma UN, Meehan K et al. IL-2 activated peripheral blood stem cell (PBSC) transplantation in breast cancer patients: patients with metastatic disease generate less potent cytotoxic effectors. Proc ASCO 1995; 14: 104 (Abstr.).
27. Hellman S. Immunotherapy for metastatic cancer. Establishing a 'proof of principle'. JAMA 1994; 271: 945-946.
28. Murphy WJ, Keller JR, Harrison CL et al. Interleukin-2 activated natural killer cells can support hematopoiesis in vitro and promote marrow engraftment in vivo. Blood 1992; 80: 670-677.